Advancing Precision Oncology with New Tumor Organoids
Patient-derived tumor organoids are emerging as high-fidelity preclinical models for precision oncology, offering a way to test cancer treatments on three-dimensional cell clusters that mirror a patient’s specific disease. Recent research led by investigators at Weill Cornell Medicine demonstrates that these “avatars” can reliably predict treatment sensitivity, potentially expanding the pool of patients eligible for … Read more